MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farmer, S. G.
Right arrow Articles by Wilkins, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farmer, S. G.
Right arrow Articles by Wilkins, D. E.

Evidence for a pulmonary B3 bradykinin receptor

SG Farmer, RM Burch, SA Meeker and DE Wilkins

Nova Pharmaceutical Corporation, Baltimore, Maryland 21224-2788.

We have examined pulmonary effects of bradykinin (Bk) in vivo and in vitro in guinea pigs and their potential inhibition by antagonists of Bk B1 and B2 receptors. Bk was a potent bronchoconstrictor in vivo and caused contractions of isolated, epithelium-denuded trachealis. D- Arg[Hyp3,D-Phe7]-Bk (NPC567) and D-arg[Hyp3,Thi5,8,D-Phe7]-Bk (NPC349), B2 receptor antagonists, were weak inhibitors of Bk-induced bronchoconstriction in vivo and were virtually inactive as antagonists of Bk-induced airway smooth muscle contraction. Several other B2 antagonists as well as B1 antagonist, des-Arg9-[Leu8]-Bk, did not inhibit Bk-induced tracheal contraction. The B1 receptor agonist des- Arg9-Bk was without effect on tracheal tone. Tracheal responses to Bk were unaffected by antagonists of muscarinic, histamine, serotonin, and catecholamine receptors. The inability of the antagonists to inhibit Bk is unlikely to be due to their degradation, because NPC567 was only weakly active in the presence of inhibitors of kininase I (EC 3.4.11.2), kininase II (EC 3.4.15.1), and neutral endopeptidase (EC 3.4.24.11). These studies were corroborated by ligand binding experiments in guinea pig and ovine airways. In [3H]Bk binding, the Bk antagonists had no effect in guinea pig trachea, slightly displaced [3H]Bk in ovine trachea, and inhibited approximately 60% of total specific binding in lung. des-Arg9-[Leu8]-Bk and several other agents, including atropine, neurokinin A, substance P, and vasoactive intestinal peptide, had no effect on lung Bk binding. Bk and its analogs were not degraded during the binding assay. These data suggest that pulmonary tissue, particularly in the large airways, contains a novel Bk binding site, a B3 receptor, which may be involved in Bk- induced bronchoconstriction.

Volume 36, Issue 1, pp. 1-8, 07/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
D. Mehta and A. B. Malik
Signaling Mechanisms Regulating Endothelial Permeability
Physiol Rev, January 1, 2006; 86(1): 279 - 367.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Valenti, C. Cialdai, S. Giuliani, A. Lecci, M. Tramontana, S. Meini, L. Quartara, and C. A. Maggi
MEN16132, a Novel Potent and Selective Nonpeptide Kinin B2 Receptor Antagonist: In Vivo Activity on Bradykinin-Induced Bronchoconstriction and Nasal Mucosa Microvascular Leakage in Anesthetized Guinea Pigs
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 616 - 623.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
P. A. Leonard, R. Arunkumar, and T. J. Brennan
Bradykinin Antagonists Have No Analgesic Effect on Incisional Pain
Anesth. Analg., October 1, 2004; 99(4): 1166 - 1172.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J. N. Sharma
Does the Kinin System Mediate in Cardiovascular Abnormalities? An Overview
J. Clin. Pharmacol., November 1, 2003; 43(11): 1187 - 1195.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Koyama, E. Sato, H. Numanami, K. Kubo, S. Nagai, and T. Izumi
Bradykinin Stimulates Lung Fibroblasts to Release Neutrophil and Monocyte Chemotactic Activity
Am. J. Respir. Cell Mol. Biol., January 1, 2000; 22(1): 75 - 84.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
S. Koyama, E. Sato, H. Nomura, K. Kubo, M. Miura, T. Yamashita, S. Nagai, and T. Izumi
Bradykinin Stimulates Type II Alveolar Cells to Release Neutrophil and Monocyte Chemotactic Activity and Inflammatory Cytokines
Am. J. Pathol., December 1, 1998; 153(6): 1885 - 1893.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. Pang and A. J. Knox
PGE2 release by bradykinin in human airway smooth muscle cells: involvement of cyclooxygenase-2 induction
Am J Physiol Lung Cell Mol Physiol, December 1, 1997; 273(6): L1132 - L1140.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Dumitriu, S. Prié, S. G. Bernier, G. Guillemette, and P. Sirois
Mechanism of Action of Leukotriene D4 on Guinea Pig Tracheal Smooth Muscle Cells: Roles of Ca++ Influx and Intracellular Ca++ Release
J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1357 - 1365.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. A. Borkowski, R. W. Ransom, G. R. Seabrook, M. Trumbauer, H. Chen, R. G. Hill, C. D. Strader, and J. F. Hess
Targeted Disruption of a B[IMAGE] Bradykinin Receptor Gene in Mice Eliminates Bradykinin Action in Smooth Muscle and Neurons
J. Biol. Chem., June 9, 1995; 270(23): 13706 - 13710.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics